| Large-scale association analyses identify host factors influencing human gut microbiome composition A Kurilshikov, C Medina-Gomez, R Bacigalupe, D Radjabzadeh, J Wang, ... Nature genetics 53 (2), 156-165, 2021 | 806 | 2021 |
| Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome A Vich Vila, F Imhann, V Collij, SA Jankipersadsing, T Gurry, Z Mujagic, ... Science translational medicine 10 (472), eaap8914, 2018 | 448 | 2018 |
| Understanding the role of tryptophan and serotonin metabolism in gastrointestinal function D Keszthelyi, FJ Troost, AAM Masclee Neurogastroenterology & Motility 21 (12), 1239-1249, 2009 | 410 | 2009 |
| Leaky gut and diabetes mellitus: what is the link? S De Kort, D Keszthelyi, AAM Masclee Obesity Reviews 12 (6), 449-458, 2011 | 267 | 2011 |
| Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome D Keszthelyi, FJ Troost, AA Masclee American Journal of Physiology-Gastrointestinal and Liver Physiology 303 (2 …, 2012 | 199 | 2012 |
| Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review Z Vinarov, M Abdallah, JAG Agundez, K Allegaert, AW Basit, ... European Journal of Pharmaceutical Sciences 162, 105812, 2021 | 184 | 2021 |
| Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review C Stillhart, K Vučićević, P Augustijns, AW Basit, H Batchelor, TR Flanagan, ... European Journal of Pharmaceutical Sciences 147, 105280, 2020 | 181 | 2020 |
| Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case–control study D Keszthelyi, SV Jansen, GA Schouten, S De Kort, B Scholtes, L Engels, ... Alimentary pharmacology & therapeutics 32 (9), 1124-1128, 2010 | 133 | 2010 |
| United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia L Wauters, R Dickman, V Drug, A Mulak, J Serra, P Enck, J Tack, ... Neurogastroenterology & Motility 33 (9), e14238, 2021 | 125 | 2021 |
| Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to … Z Mujagic, S Ludidi, D Keszthelyi, MAM Hesselink, JW Kruimel, ... Alimentary pharmacology & therapeutics 40 (3), 288-297, 2014 | 122 | 2014 |
| Impaired defense mechanism against inflammation, hyperalgesia, and airway hyperreactivity in somatostatin 4 receptor gene-deleted mice Z Helyes, E Pintér, K Sándor, K Elekes, Á Bánvölgyi, D Keszthelyi, ... Proceedings of the National Academy of Sciences 106 (31), 13088-13093, 2009 | 113 | 2009 |
| Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome ZZRM Weerts, AAM Masclee, BJM Witteman, CHM Clemens, B Winkens, ... Gastroenterology 158 (1), 123-136, 2020 | 107 | 2020 |
| Rome III vs Rome IV criteria for irritable bowel syndrome: a comparison of clinical characteristics in a large cohort study L Vork, ZZRM Weerts, Z Mujagic, JW Kruimel, MAM Hesselink, JWM Muris, ... Neurogastroenterology & Motility 30 (2), e13189, 2018 | 101 | 2018 |
| Rectal hypersensitivity as hallmark for irritable bowel syndrome: defining the optimal cutoff S Ludidi, JM Conchillo, D Keszthelyi, M Van Avesaat, JW Kruimel, ... Neurogastroenterology & Motility 24 (8), 729-e346, 2012 | 95 | 2012 |
| Ethanol impairs intestinal barrier function in humans through mitogen activated protein kinase signaling: a combined in vivo and in vitro approach E Elamin, A Masclee, F Troost, HJ Pieters, D Keszthelyi, K Aleksa, ... PloS one 9 (9), e107421, 2014 | 82 | 2014 |
| Gastrointestinal disorders in joint hypermobility syndrome/Ehlers‐Danlos syndrome hypermobility type: A review for the gastroenterologist AB Beckers, D Keszthelyi, A Fikree, L Vork, A Masclee, AD Farmer, Q Aziz Neurogastroenterology & Motility 29 (8), e13013, 2017 | 81 | 2017 |
| The enteric nervous system in gastrointestinal disease etiology AM Holland, AC Bon-Frauches, D Keszthelyi, V Melotte, W Boesmans Cellular and Molecular Life Sciences 78 (10), 4713-4733, 2021 | 77 | 2021 |
| Effects of the somatostatin receptor subtype 4 selective agonist J‐2156 on sensory neuropeptide release and inflammatory reactions in rodents Z Helyes, E Pintér, J Németh, K Sándor, K Elekes, Á Szabó, G Pozsgai, ... British journal of pharmacology 149 (4), 405-415, 2006 | 75 | 2006 |
| Alterations in serotonin metabolism in the irritable bowel syndrome AY Thijssen, Z Mujagic, D Jonkers, S Ludidi, D Keszthelyi, MA Hesselink, ... Alimentary Pharmacology & Therapeutics 43 (2), 272-282, 2016 | 70 | 2016 |
| Role of TRPV1 and TRPA1 ion channels in inflammatory bowel diseases: potential therapeutic targets? K Csekő, B Beckers, D Keszthelyi, Z Helyes Pharmaceuticals 12 (2), 48, 2019 | 69 | 2019 |
Magnus SimrénProfessor i GastroenterologiVerified email at medicine.gu.se
